Search

A new study from Memorial Sloan Kettering Cancer Center (MSK) provides important insights into cancer metastasis.  

… Thursday, February 3, 2022 New findings from researchers at Memorial Sloan Kettering Cancer Center (MSK), and published today in the journal Cell , support an emerging framework in cancer science that views metastasis as not primarily driven by genetic mutations, but rather by epigenetic changes that

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

… Monday, October 31, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Luis Diaz Luis Diaz Jr. Recognized with a 2022 El Award by New York’s El Diario Luis Alberto Diaz, Jr., MD , medical oncologist, Head Division of Solid Tumor Oncology, and Grayer Family

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Tuesday, March 28, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: MSK Granted Merit Extension from the National Cancer Institute MSK was granted a prestigious two-year merit extension of its Cancer Center Support Grant from the National Cancer

Meet Sheree Scarlett, who helps to promote the wellness-related resources available to employees in her role in Employee Health and Wellness Services at MSK.

… Tuesday, February 1, 2022 In her role in Employee Health and Wellness Services at Memorial Sloan Kettering Cancer Center, Sheree Scarlett helps to promote the wellness-related resources available to employees, including the recently launched Guided Wellbeing program. Sheree was born in Kingston, Jamaica

Read about an antibody-drug conjugate treatment for HR+, HER2- breast cancer.

… Wednesday, December 10, 2025 People with hormone receptor (HR)-positive, HER2-negative  breast cancer that has spread (metastasized) usually receive  endocrine therapy as the first treatment. These breast cancers often ultimately become resistant to endocrine therapy and continue growing. At this point

Cancer treatments like chemotherapy may cause cognitive changes, which experts call “chemo brain.” Learn how Memorial Sloan Kettering experts help patients with this condition.

… Tuesday, May 3, 2016 Summary Patients undergoing chemotherapy sometimes experience “chemo brain,” a frustrating ailment marked by cognitive changes that can sometimes mimic other conditions. MSK offers help from  occupational therapists like Grace Chen , who help patients experiencing chemo brain to

The lack of participation in clinical research may be the Achilles’ heel of today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of Memorial Sloan Kettering Cancer Center (MSK), only 35 percent of Americans indicated that they were “likely” to enroll in a clinical trial. Other studies have shown that only 4 percent of cancer patients enroll in clinical trials nationally each year.

… Monday, May 23, 2016 The lack of participation in clinical research may be the Achilles’ heel of today’s cancer community. According to a new survey of more than 1,500 consumers and nearly 600 physicians conducted on behalf of Memorial Sloan Kettering Cancer Center (MSK), only 35 percent of Americans

A study from MSK takes a deeper look at some of the causes of secondary leukemia.

… Monday, September 9, 2019 Summary A new study from Memorial Sloan Kettering suggests that in some people treated for breast cancer, leukemia-causing gene mutations may be present in blood cells from the time the original cancer was diagnosed. This helps explain some cases of secondary leukemia. Doctors

it means to survive cancer and learn how MSK is honoring all cancer survivors this year during National Cancer Survivor Month.

… Wednesday, June 17, 2020 Seth Frankel sitting in a red chair “Being a cancer survivor is a little bit like being a superhero: Not everyone will know your secret identity, but you have an ability to summon a hidden strength that can overcome any obstacle standing in your way.” — Seth Frankel, age 39,

Martin S. Tallman, MD, has been appointed Chief of the Leukemia Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Cornell Medical College.

… Tuesday, May 11, 2010 Martin S. Tallman, MD, has been appointed Chief of the Leukemia Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Cornell Medical College. “We are very fortunate to have Dr. Tallman join the Memorial Sloan Kettering